Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Receivables (2023 - 2025)

Historic Change in Receivables for Fennec Pharmaceuticals (FENC) over the last 3 years, with Q3 2025 value amounting to $3.4 million.

  • Fennec Pharmaceuticals' Change in Receivables fell 1809.52% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year decrease of 2360.89%. This contributed to the annual value of $7.9 million for FY2024, which is 830.93% up from last year.
  • Per Fennec Pharmaceuticals' latest filing, its Change in Receivables stood at $3.4 million for Q3 2025, which was down 1809.52% from $265000.0 recorded in Q2 2025.
  • Fennec Pharmaceuticals' 5-year Change in Receivables high stood at $5.3 million for Q1 2025, and its period low was $138000.0 during Q1 2023.
  • Over the past 3 years, Fennec Pharmaceuticals' median Change in Receivables value was $2.0 million (recorded in 2024), while the average stood at $2.2 million.
  • Examining YoY changes over the last 5 years, Fennec Pharmaceuticals' Change in Receivables showed a top increase of 95797.1% in 2024 and a maximum decrease of 9591.98% in 2024.
  • Over the past 3 years, Fennec Pharmaceuticals' Change in Receivables (Quarter) stood at $4.3 million in 2023, then crashed by 95.92% to $175000.0 in 2024, then skyrocketed by 1865.71% to $3.4 million in 2025.
  • Its Change in Receivables was $3.4 million in Q3 2025, compared to $265000.0 in Q2 2025 and $5.3 million in Q1 2025.